This text-based CME activity provides guidance and expert recommendations on the initial diagnostic workup and therapy selection, as well as an overview of the latest data on recently approved and emerging therapeutic options for patients with B-cell non-Hodgkin lymphoma (NHL). Although recent treatment advances do not provide a cure, they do, however, provide longer remissions and improve patient outcomes. We invite you to learn more about the current standard of care, recently approved treatment options, including PI3K inhibitors, as well as safety and efficacy data from the select clinical trials.
This activity was developed for hematologists/oncologists, hematologists, medical oncologists and other healthcare providers who care for patients with Non-Hodgkin Lymphoma (NHL).
|Available Credit:||1.00 AMA PRA Category 1 Credit™.|
|Opens:||September 07, 2018|
|Expires:||September 06, 2019|
Other Healthcare Providers